Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core

被引:17
|
作者
Xu, Jin [1 ,2 ]
Ong, Esther H. Q. [3 ]
Hill, Jeffrey [3 ]
Chen, Anqi [1 ]
Chai, Christina L. L. [1 ,2 ]
机构
[1] ASTAR, ICES, Singapore 138665, Singapore
[2] Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore
[3] ETC, Singapore 138669, Singapore
关键词
FLT3; Covalent inhibitor; Michael acceptor; Maleimide; Acrylamide; Resorcylic acid lactones; PROTEIN-KINASE INHIBITORS; RECEPTOR TYROSINE KINASE; IRREVERSIBLE INHIBITORS; THERAPEUTIC TARGET; DISCOVERY; POTENT; AFATINIB; ANALOGS; GROWTH; CANCER;
D O I
10.1016/j.bmc.2014.10.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of simplified ring-opened resorcylic acid lactone (RAL) derivatives were conveniently synthesized to target FLT3 and its mutants either irreversibly or reversibly. Our design of covalent FLT3 inhibitors is based on cis-enone RALs (e.g., L-783,277) that have a beta-resorcylic acid as the core structure. The designed compounds contain three types of Michael acceptors (acrylamide, vinylsulfonamide and maleimide) as potential covalent traps of a cysteine residue at the binding site of kinases. A variety of functional substitutions were also introduced to maximize the binding interactions. Biological evaluations revealed that compound 17, despite the presence of a highly reactive maleimide Michael acceptor, is a potent covalent FLT3 inhibitor which shows some specificity in cellular assays. On the other hand, compounds 2 and 6 containing acrylamide or vinylsulfonamide groups are reversible towards FLT3 binding, and are potent and selective inhibitors of mutant FLT3-ITD versus wt-FLT3. They also inhibit cell proliferation in FLT3-ITD expressing cell line MV-4-11 as compared to wt-FLT3 expressing cell line THP-1 and non-FLT3 cell lines (K562, HL60 and Hek-293T). (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6625 / 6637
页数:13
相关论文
共 50 条
  • [21] FLT3 tyrosine kinase inhibitors
    Levis, M
    Small, D
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (02) : 100 - 107
  • [22] Use of FLT3 Inhibitors in AML
    Smith, Catherine C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S92 - S94
  • [23] FLT3 inhibitors tested in LAM
    Rousselot, Philippe
    HEMATOLOGIE, 2007, 13 (01): : 15 - 15
  • [24] Mechanisms of resistance to FLT3 inhibitors
    Chu, S. Haihua
    Small, Donald
    DRUG RESISTANCE UPDATES, 2009, 12 (1-2) : 8 - 16
  • [25] Rethinking bioactivity of FLT3 inhibitors
    Fischer, Thomas
    BLOOD, 2011, 117 (12) : 3247 - 3248
  • [26] FLT3 Tyrosine Kinase Inhibitors
    Mark Levis
    Donald Small
    International Journal of Hematology, 2005, 82 : 100 - 107
  • [27] Biological activities of FLT3 ligand
    Lyman, SD
    Brasel, K
    Maraskovsky, E
    Miller, RE
    Schuh, J
    Maliszewski, C
    Pulendran, B
    Stocking, K
    Peschon, J
    Lynch, D
    McKenna, H
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 7 - 7
  • [28] Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors
    Genovese, Filippo
    Lazzari, Sandra
    Venturi, Ettore
    Costantino, Luca
    Blazquez, Jesus
    Ibacache-Quiroga, Claudia
    Costi, Maria Paola
    Tondi, Donatella
    MEDICINAL CHEMISTRY RESEARCH, 2017, 26 (05) : 975 - 986
  • [29] Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4
    Chen, Xiaojuan
    Li, Huiliang
    Lin, Qianmeng
    Dai, Shuyan
    Qu, Lingzhi
    Guo, Ming
    Zhang, Lin
    Liao, Jiaxuan
    Wei, Hudie
    Xu, Guangyu
    Jiang, Longying
    Chen, Yongheng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 268
  • [30] Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors
    Filippo Genovese
    Sandra Lazzari
    Ettore Venturi
    Luca Costantino
    Jesus Blazquez
    Claudia Ibacache-Quiroga
    Maria Paola Costi
    Donatella Tondi
    Medicinal Chemistry Research, 2017, 26 : 975 - 986